LV305, a dendritic cell-targeting integration-deficient ZVex(TM)-based lentiviral vector encoding NY-ESO-1, induces potent anti-tumor immune response.
We have engineered an integration-deficient lentiviral vector, LV305, to deliver the tumor antigen NY-ESO-1 to human dendritic cells in vivo through pseudotyping with a modified Sindbis virus envelop protein. Mice immunized once with LV305 developed strong, dose-dependent, multifunctional, and cytotoxic NY-ESO-1-specific cluster of differentiation 8 (CD8) T cells within 14 days post-immunization and could be boosted with LV305 at least twice to recall peak-level CD8 T-cell responses. Immunization with LV305 protected mice against tumor growth in an NY-ESO-1-expressing CT26 lung metastasis model, with the protective effect abrogated upon depletion of CD8 T cells. Adoptive transfer of CD8 T cells, alone or together with CD4 T cells or natural killer cells, from LV305-immunized donor mice to tumor-bearing recipient mice conferred significant protection against metastatic tumor growth. Biodistribution of injected LV305 in mice was limited to the site of injection and the draining lymph node, and injected LV305 exhibited minimal excretion. Mice injected with LV305 developed little to no adverse effects, as evaluated by toxicology studies adherent to good laboratory practices. Taken together, these data support the development of LV305 as a clinical candidate for treatment against tumors expressing NY-ESO-1.
In Vivo Biology, Immune Design , Seattle, Washington, USA.
Tina Chang
TC
Albershardt
In Vivo Biology, Immune Design , Seattle, Washington, USA.
David James
DJ
Campbell
In Vivo Biology, Immune Design , Seattle, Washington, USA.
Andrea Jean
AJ
Parsons
In Vivo Biology, Immune Design , Seattle, Washington, USA.
Megan Merrill
MM
Slough
In Vivo Biology, Immune Design , Seattle, Washington, USA.
Jan
J
Ter Meulen
In Vivo Biology, Immune Design , Seattle, Washington, USA.
Peter
P
Berglund